1[1]Wong PC,Timmers PB.Historical development of losartan(Dup 753) and angiotensin Ⅱ receptor subtypes[J].Blood(Press Suppl),1996,3:11-14.
2[2]Burell LM.A risk-benefit assessment of losartan potassium in the tr eatment of hypertension[J].Drug,1997,16(1):56-65.
3[3]Flesch G,Muller P,Lloyd P.Absolute bioavailability and pharmacokinet i cs of valsartan,an angiotensin Ⅱ receptor antagonist,in man[J].Eur J Clin Pha rmacol,1997,52(2):115-120.
4[4]Gavras H.Angiotensin Ⅱ antagonism:a new avenue of hypertension mana gement[J].Blood(Press Suppl),1997,1:42-46.
5[5]Rakugi H,Ogihara T.Angiotensin receptor antagonist for therapy of pa tients with hypertension[J].Nippon Rinsho,1997,55(8):2075-2080.
6[6]Neutel J,Weber M,Pool J,et al.Valsartan,a new angiotensin Ⅱ antagon ist:antihypertensive effects over 24 hours[J].Clin Ther,1997,19(3):447-458.[ ZK)〗
7[7]Hegner G,Faust G,Fraytag F,et al.Valsartan,a new angiotensin Ⅱ anta gonist for the treatment of essentail hypertension:efficacy and safety compared to hydrochlorothiazide[J].Eur J Clin Pharmacol,1997,52(3):173-177.
8[8]Cifkova R,Peleska J,Hradec J,et al.Valsartan and atenolol in patient s with severe essential hypertension[J].J Hum Hypertens,1998,12(8):563-567.[ ZK)〗
9[9]Benz JR,Black HE,Graff A,et al.Valsartan and hydrochlorothiazide in patients with essential hypertension.A multiple dose,double-blind,placebo contr olled trial comparing combination therapy with monotherapy[J].J Hum Hypertens, 1998,12(12):861-866.
10[10]Blacd HR,Graff A,Shute D,et al.Valsartan,a new angiotensin Ⅱ antag onist for the treatment of essential hypertension:efficacy,tolerability and safe ty compared to an angiotensin-converting enzyme inhibitor,lisiropril[J].J Hum Hypertens,1997,11(8):483-489.
